Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | PCNA | P12004 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12837224 | 0.93 | EPHX2 (0.43) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL1526151 | 0.86 | THRB (0.60) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL12584523 | 0.84 | THRB (0.36) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL1525943 | 0.84 | EPHX2 (0.42) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL17365412 | 0.82 | THRB (0.55) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL16124428 | 0.81 | PCNA (0.67) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL19696689 | 0.80 | THRB (0.35) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL12837226 | 0.80 | THRB (0.52) | EPHX2POLBTHRBTHRARXRA | |
| SCHEMBL16155956 | 0.80 | THRB (0.68) | POLBTHRBTHRARXRAPPARG | |
| SCHEMBL6857392 | 0.79 | THRB (0.52) | POLBTHRBTHRARXRAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2442800-B1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2442800-B1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9839614-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160199309-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS, LLC | 2016-07-14 | — | — | US | disclosed |
| US-9220788-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220788-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-8802240-B2 | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells | NANOPHARMACEUTICALS LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802240-B2 | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells | NANOPHARMACEUTICALS LLC (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2662079-A1 | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells | Ordway Research Institute, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2662079-A1 | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells | Ordway Research Institute, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | NANOPHARMACEUTICALS LLC | 2012-12-13 | — | — | US | disclosed |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | NANOPHARMACEUTICALS LLC | 2012-12-13 | — | — | US | disclosed |
| EP-2442800-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | Ordway Research Institute, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010148007-A9 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | ORDWAY RESEARCH INSTITUTE, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110052715-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC | 2011-03-03 | — | — | US | disclosed |
| WO-2010148007-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | ORDWAY RESEARCH INSTITUTE, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199309-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | TSHR, THRA, TRHR | EPHX2 2794/4885POLB 4291/4885THRB 4/4885 |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | TSHR, TPO, THRA | EPHX2 3877/4885POLB 3807/4885THRB 5/4885 |
| US-20110052715-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | TSHR, THRA, TRHR | EPHX2 2794/4885POLB 4291/4885THRB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.